|
Planned dosimetric quantities
| | |
|
Breast PTV Eval
| | |
|
D95% [%]
|
97.73 (93.63–98.64)
|
–
|
|
V90% [%]
|
99.50 (95.50–100.00)
|
–
|
|
V105% [%]
|
0.10 (0.00–41.10)
|
–
|
|
BODY
| | |
|
V90% [cc]
|
1174.64 (863.13–1698.72)
|
–
|
|
V105% [cc]
|
3.67 (0.00–390.63)
|
–
|
|
Global max dose [%]
|
105.59 (104.94–106.92)
|
–
|
|
Daily dosimetric quantities
| | |
|
Breast PTV Eval
| | |
|
D95% [%]
|
97.74 (82.56–99.51)a
|
N.S
|
|
V90% [%]
|
99.30 (94.20–100.00)a
|
N.S
|
|
V105% [%]
|
13.15 (0.00–72.50)b
|
1.5 × 10−4
|
|
BODY
| | |
|
V90% [cc]
|
1107.75 (831.38–1905.60)
|
–
|
|
V105% [cc]
|
130.45 (0.00–640.39)a,c
|
N.S
|
|
Global max dose [%]
|
108.85 (104.92–115.08)b
|
4.4 × 10−16
|
|
Difference from prescribed (Δ)
| | |
|
Breast PTV Eval
| | |
|
ΔD95% [%]
|
− 0.04 (− 11.07 to 1.78)
|
N.S
|
|
ΔV90% [%]
|
− 0.10 (− 1.70 to 0.20)*
|
6.1 × 10−11
|
|
ΔV105% [%]
|
+ 10.10 (− 15.40 to 72.50)*
|
6.3 × 10−16
|
|
BODY
| | |
|
ΔV90% [cc]
|
− 18.07 (− 155.14 to 206.87)*
|
3.4 × 10−3
|
|
ΔV105% [cc]
|
+ 92.40 (− 120.24 to 596.96)*
|
9.4 × 10−18
|
|
ΔGlobal max dose [%]
|
+ 2.43 (− 3.02 to 6.59)*
|
6.7 × 10−17
|
